Provides Update Regarding Closing Date of Transaction with Alzex Biomedical Group Inc.
REBEL CAPITAL 2.0 CORP.
PROVIDES UPDATE REGARDING CLOSING DATE OF TRANSACTION WITH
ALZEX BIOMEDICAL GROUP INC.
TSX Venture: RBZ.P FOR IMMEDIATE RELEASE
CALGARY, ALBERTA – September 17, 2020 – Rebel Capital 2.0 Corp. (" Rebel" or the
"Corporation") provides an update on the previously announced transaction whereby Rebel
expects to complete a business combination with Alzex Biomedical Group Inc. ( “Alzex”)
pursuant to a an amended definitive agreement dated May 7, 2020 (with effect as and from
March 31, 2020) between Rebel and Alzex (the “Definitive Agreement”) that, if completed
by the closing date of September 15, 2020, would constitute Rebel's "Qualifying Transaction"
(as such term is defined in TSX Venture Exchange (" TSXV") Policy 2.4 – Capital Pool
Companies) (the "Transaction").
Rebel and Alzex have not completed the Transaction noted above by the September 15, 2020
deadline. The parties agree to continue discussions and agree to terms to set a new closing
date of the Transaction.
Further information regarding the Transaction is provided in Rebel’s press releases dated
September 30, 2019, January 7, 2020, and May 8, 2020 available under Rebel’s profile on
www.sedar.com.
About Rebel Capital 2.0 Corp
Rebel Capital is a capital pool company ("CPC") within the meaning of the policies of the TSXV
that has not commenced commercial operations and has no assets other than cash. The board
of directors of the Corporation consist of Charles MaLette, Doug Bachman and Lance Morginn.
The officers of the Corporation are Charles MaLette (CEO), and Lance Morginn (CFO).
Completion of the Transaction is subject to a number of conditions including, but not limited to, TSXV
acceptance. Where applicable, the Transaction cannot close until the required shareholder approval is
obtained. There can be no assurance that the Transaction will be completed as proposed or at all.
Investors are cautioned that, except as disclosed in the Filing Statement to be prepared in connection
with the Transaction, any information released or received with respect to the Transaction may not be
accurate or complete and should not be relied upon. Trading in the securities of a capital pool company
should be considered highly speculative.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed Transaction and
has neither approved nor disapproved the contents of this Press Release.
For further information please contact:
Rebel Capital 2.0 Corp.: Alzex Bio Medical Inc.:
Charles MaLette Fern Turner – Director
Email: [email protected] Email: [email protected]
Telephone: (604) 428-5171